StageZero Life Sciences Completes $4.6 Million Prospectus Offering

June 29, 2020

StageZero Life Sciences Ltd. (TSX:SZLS) completed a public offering of 66,176,100 units for aggregate gross proceeds of over $4.6 million. The offering was co-led by Echelon Wealth Partners Inc. and Clarus Securities Inc.

StageZero operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. As a specialist in PCR testing for the early identification of cancer through blood, the company is positioned to provide both COVID-19 PCR testing (nasal swab) and blood test analysis (antibody testing) during the pandemic.

Wildeboer Dellelce LLP acted for the agents in connection with the offering with a team that included Michael Rennie, Carlye Bellavia and Jessica Sorbara (corporate/securities) and Katy Pitch and Marija Tasevska (tax).